Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice

Psychopharmacology

Volumn 170, Issue 2, 2003, Pages 178-187

  Risbrough, Victoria B ^a   Hauger, Richard L ^b,c   Pelleymounter, Mary Ann ^d,e   Geyer, Mark A ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d NEUROCRINE BIOSCIENCES INC   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Acoustic startle; Antisauvagine 30; Anxiety; Corticotropin releasing hormone; NBI 03775; R 121919

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; ANTISAUVAGINE 30; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR AGONIST; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; HORMONE RECEPTOR STIMULATING AGENT; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; UROCORTIN;

ACOUSTIC REFLEX; ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; HORMONAL REGULATION; INBRED STRAIN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STARTLE REFLEX;

ANIMALS; AREA UNDER CURVE; BEHAVIOR, ANIMAL; CORTICOTROPIN-RELEASING HORMONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG INTERACTIONS; MALE; MICE; MICE, INBRED STRAINS; PEPTIDE FRAGMENTS; PYRIMIDINES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SPECIES SPECIFICITY; STARTLE REACTION; TIME FACTORS;

EID: 0242492219     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1535-6     Document Type: Article

References (61)

1. Bakshi VP, Kalin NH (2000) Corticotropin-releasing hormone and animal models of anxiety: gene-environment interactions. Biol Psychiatry 48:1175-1198
2. Bakshi VP, Smith-Roe S, Newman SM, Grigoriadis DE, Kalin NH (2002) Reduction of stress-induced behavior by antagonism of corticotropin-releasing hormone 2 (CRH2) receptors in lateral septum or CRH1 receptors in amygdala. J Neurosci 22:2926-2935
3. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW, Lee KF (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 24:410-414
4. Bale TL, Picetti R, Contarino A, Koob GF, Vale WW, Lee KF (2002) Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J Neurosci 22:193-199
5. Bittencourt JC, Sawchenko PE (2000) Do centrally mediated neuropeptides access cognate receptors?: an analysis in the central corticotropin-releasing factor system. J Neurosci 20:1142-1156
6. Blank T, Nijholt I, Grammatopoulos DK, Randeva HS, Hillhouse EW, Spiess J (2003) Corticotropin-releasing factor receptors couple to multiple G-proteins to activate diverse intracellular signaling pathways in mouse hippocampus: role in neuronal excitability and associative learning. J Neurosci 23:700-707
7. Brauns O, Liepold T, Radulovic J, Spiess J (2001) Pharmacological and chemical properties of astressin, antisauvagine-30 and alpha-helical CRF: significance for behavioral experiments. Neuropharmacology 41:507-516
8. Butler RW, Braff DL, Rausch JL, Jenkins MA, Sprock J, Geyer MA (1990) Physiological evidence of exaggerated startle response in a subgroup of Vietnam veterans with combat-related PTSD. Am J Psychiatry 147:1308-1312
9. Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Erlbaum, Hillsdale, N.J.
10. Conti LH, Costello DG, Martin LA, White MF, Abreu ME (1994) Mouse strain differences in the behavioral effects of corticotropin-releasing factor (CRF) and the CRF antagonist alpha-helical CRF9-41. Pharmacol Biochem Behav 48:497-503
11. Coste SC, Murray SE, Stenzel-Poore MP (2001) Animal models of CRH excess and CRH receptor deficiency display altered adaptations to stress. Peptides 22:733-741
12. Dautzenberg FM, Hauger RL (2002) The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 23:71-77
13. Davis M (1998) Are different parts of the extended amygdala involved in fear versus anxiety? Biol Psychiatry 44:1239-1247
14. Davis M, Falls WA, Campeau S, Kim M (1993) Fear-potentiated startle: a neural and pharmacological analysis. Behav Brain Res 58:175-198
15. Davis M, Walker DL, Lee Y (1997) Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex. Possible relevance to PTSD. Ann NY Acad Sci 821:305-331
16. 4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J Neurosci 19:9550-9556
17. Fendt M, Fanselow MS (1999) The neuroanatomical and neurochemical basis of conditioned fear. Neurosci Biobehav 23:743-760
18. Graeff FG, Silveira MC, Nogueira RL, Audi EA, Oliveira RM (1993) Role of the amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res 58:123-131
19. Griebel G, Perrault G, Sanger DJ (1998) Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology 138:55-66
20. Grigoriadis DE, Chen C, Wilcoxen K, Chet T, Lorang MT, Bozigion H, Lia X-J, Ling N, McCarthy JR, De Souza EB, Vale WW (2000) In vitro characterization of R121292: a novel non-peptide corticotropin-releasing factor1 (CRF1) receptor antagonist for the potential treatment of depression and anxiety-related disorders. Soc Neurosci Abstr 807:4-9
21. Grigoriadis D, Haddach M, Ling N, Saunders J (2001) The CRF receptor: structure, function and potential for therapeutic intervention. Curr Med Chem-CNS Agents 1:63-97
22. Grillon C (2002) Associative learning deficits increase symptoms of anxiety in humans. Biol Psychiatry 51:958-975
23. Grillon C, Morgan CA 3rd (1999) Fear-potentiated startle conditioning to explicit and contextual cues in Gulf War veterans with posttraumatic stress disorder. J Abnorm Psychol 108:134-142
24. Grillon C, Morgan CA 3rd, Davis M, Southwick SM (1998) Effects of experimental context and explicit threat cues on acoustic startle in Vietnam veterans with posttraumatic stress disorder. Biol Psychiatry 44:1027-1036
25. 1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J Pharmacol Exp Ther 304:874-880
26. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, Chrousos GP, McCann SM, Suomi SJ, Higley JD, Gold PW (2000) Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 97:6079-6084
27. Heinrichs SC, De Souza EB, Schulteis G, Lapsansky JL, Grigoriadis DE (2002) Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 27:194-202
28. Heldt S, Sundin V, Willott JF, Falls WA (2000) Posttraining lesions of the amygdala interfere with fear-potentiated startle to both visual and auditory conditioned stimuli in C57BL/6J mice. Behav Neurosci 114:749-759
29. 125I-Antisauvagine-30: a novel and specific high affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors. Neuropharmacology 40:114-122
30. Ho SP, Takahashi LK, Livanov V, Spencer K, Lesher T, Maciag C, Smith MA, Rohrbach KW, Hartig PR, Arneric SP (2001) Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor. Brain Res Mol Brain 89:29-40
31. Jones DN, Kortekaas R, Slade PD, Middlemiss DN, Hagan JJ (1998) The behavioural effects of corticotropin-releasing factor-related peptides in rats. Psychopharmacology 138:124-132
32. Keck ME, Welt T, Wigger A, Renner U, Engelmann M, Holsboer F, Landgraf R (2001) The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 13:373-380
33. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F, Hermanson O, Rosenfeld MG, Spiess J (2000) Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24:415-419
34. Koob GF, Heinrichs SC (1999) A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res 848:141-152
35. Lang PJ, Davis M, Ohman A (2000) Fear and anxiety: animal models and human cognitive psychophysiology. J Affect Disord 61:137-159
36. Liang KC, Melia KR, Miserendino MJ, Falls WA, Campeau S, Davis M (1992) Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex. J Neurosci 12:2303-2312
37. Liebsch G, Landgraf R, Engelmann M, Lörscher P, Hoslboer F (1999) Differential behavioural effects of chronic infusion of CRH1 and CRH2 receptor antisense oligonucleotides into the rat brain. J Psychiatr Res 33:153-163
38. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB, Oltersdorf T (1995) Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 92:836-840
39. Lundkvist J, Chai Z, Teheranian R, Hasanvan H, Bartfai T, Jenck F, Widmer U, Moreau JL (1996) A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur J Pharmacol 309:195-200
40. 1A receptor ligands. Eur J Pharmacol 156:375-383
41. Nemeroff CB (2002) New directions in the development of antidepressants: the interface of neurobiology and psychiatry. Hum Psychopharmacol 17:13-16
42. Pelleymounter MA, Joppa M, Carmouche M, Cullen MJ, Brown B, Murphy B, Grigoriadis DE, Ling N, Foster AC (2000) Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF. J Pharmacol Exp Ther 293:799-806
43. Pelleymounter MA, Joppa M, Ling N, Foster AC (2002) Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. J Pharmacol Exp Ther 302:145-152
44. Perrin MH, Vale W (2002) Chapter 25: Corticotropin-releasing factor receptors. In: Pangalos MN, Davies CH (eds) Understanding G protein-coupled receptors and their role in the CNS. Oxford University Press, New York, pp 505-526
45. Radulovic J, Ruhmann A, Liepold T, Spiess J (1999) Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci 19:5016-5025
46. Reul JM, Holsboer F (2002) Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2:23-33
47. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE (2001) Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98:2843-2848
48. 1A receptor agonists block expression of fear-potentiated startle in mice. Neuropsychopharmacology 28:654-663
49. Ruhmann A, Bonk I, Lin CR, Rosenfeld MG, Spiess J (1998) Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2β-selective antisauvagine-30. Proc Natl Acad Sci USA 95:15264-15269
50. Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T, Seymour P, Tingley FD III, Winston EN, Chen YL, Heym J (1996) CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 93:10477-10482
51. Skutella T, Probst JC, Renner U, Hoslboer F, Behl C (1998) Corticotropin-releasing hormone receptor (type 1) antisense targeting reduces anxiety. Neuroscience 85:795-805
52. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W, Lee KF (1998) Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093-1102
53. Spina M, Merlo-Pich E, Chan RK, Basso AM, Rivier J, Vale W, Koob GF (1996) Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 273:1561-1564
54. Swerdlow NR, Geyer MA, Vale WW, Koob GF (1986) Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology 88:147-152
55. Swerdlow NR, Britton KT, Koob GF (1989) Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by alpha-helical CRF (9-41). Neuropsychopharmacology 2:285-292
56. Takahashi LK, Ho SP, Livanov V, Graciani N, Arneric SP (2001) Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. Brain Res 902:135-142
57. Valdez GR, Inoue K, Koob GF, Rivier J, Vale W, Zorrilla EP (2002) Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res 943:142-150
58. Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213:1394-1397
59. Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C, Prins GS, Perrin M, Vale W, Sawchenko PE (2000) Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 428:191-212
60. Walker DL, Davis M (2002) Quantifying fear potentiated startle using absolute versus proportional increase scoring methods: implications for the neurocircuitry of fear and anxiety. Psychopharmacology 164:318-328
61. Walker DL, Cassella JV, Lee Y, De Lima TC, Davis M (1997) Opposing roles of the amygdala and dorsolateral periaqueductal gray in fear-potentiated startle. Neurosci Biobehav Rev 21:743-753